Next-generation sequencing (NGS) of the tumor showed an actionable BRAF V600E mutation and MET N375S mutation of germline origin with unknown actionability while immunohistochemistry testing revealed IDH 1/2 were wild-type. Here, BRAF is linked to neoplasm.